drugset
drugset / Trial / NCT00854113

Study to Determine the Safety, Tolerability, and Pharmacokinetic (PK) Profile of EGT0001474 in Healthy Volunteers

NCT00854113 ↗

Phase 1 Completed 78 enrolled Theracos
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study evaluated the safety, tolerability and pharmacokinetics of single or multiple doses of EGT0001474.

Timeline

Start
2009-02
Primary completion
2009-07
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Bexagliflozin Small molecule 2.5 mg Oral
Subject Bexagliflozin Small molecule 10 mg Oral
Subject Bexagliflozin Small molecule 50 mg Oral
Subject Bexagliflozin Small molecule 150 mg Oral

Indications

No indication recorded.